Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
Article
PubMed
CAS
Google Scholar
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. A published erratum appears in Science. 2002;297:2209.
Article
PubMed
CAS
Google Scholar
Thal DR, Rüb U, Orantes M, Braak H. Phase of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.
Article
PubMed
Google Scholar
Jagust WJ, Mormino EC. Lifespan brain activity, β-amyloid, and Alzheimer’s disease. Trends Cogn Sci. 2011;15:520–6.
Article
PubMed
PubMed Central
Google Scholar
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.
Article
PubMed
PubMed Central
Google Scholar
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9:e111–94.
Article
PubMed
PubMed Central
Google Scholar
Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat Rev Drug Discov. 2013;12:324.
Article
PubMed
CAS
Google Scholar
Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009;106:6820–5.
Article
PubMed
PubMed Central
Google Scholar
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.
Article
PubMed
CAS
Google Scholar
Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med. 2009;50:1887–94.
Article
PubMed
PubMed Central
CAS
Google Scholar
Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35.
Article
PubMed
Google Scholar
Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.
Article
PubMed
CAS
Google Scholar
Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818–22.
Article
PubMed
CAS
Google Scholar
Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol. 1989;135:309–19.
PubMed
PubMed Central
CAS
Google Scholar
Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45.
Article
PubMed
PubMed Central
Google Scholar
Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-β. Adv Pharmacol. 2012;64:27–81.
Article
PubMed
PubMed Central
CAS
Google Scholar
Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26:8–16.
Article
PubMed
PubMed Central
CAS
Google Scholar
Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40.
PubMed
CAS
Google Scholar
Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.
PubMed
CAS
Google Scholar
Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450–9.
Article
PubMed
Google Scholar
Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560–6.
Article
PubMed
CAS
Google Scholar
Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567–74.
Article
PubMed
CAS
Google Scholar
Wong KP, Wardak M, Shao W, Dahlbom M, Kepe V, Liu J, et al. Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging. 2010;37:575–88.
Article
PubMed
PubMed Central
Google Scholar
Shokouhi S, Rogers BP, Kang H, Ding Z, Claassen DO, Mckay JW, et al. Modeling clustered activity increase in amyloid-β positron emission tomographic images with statistical descriptors. Clin Interv Aging. 2015;10:759–70.
Article
PubMed
PubMed Central
Google Scholar
Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement. 2013;9:251–61.
Article
PubMed
PubMed Central
Google Scholar
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–64.
Article
PubMed
CAS
Google Scholar
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Article
PubMed
CAS
Google Scholar
Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517–27.
Article
PubMed
PubMed Central
Google Scholar
Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131–7.
Article
PubMed
Google Scholar
Peebles PJE. The large scale structure of the universe. Princeton, NJ: Princeton University Press; 1980.
Google Scholar
Torquato S. Random heterogeneous materials: microstructure and macroscopic properties. New York: Springer; 2002.
Book
Google Scholar
Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism? Nat Med. 2000;6:718–9.
Article
CAS
Google Scholar
Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048–56.
Article
PubMed
PubMed Central
CAS
Google Scholar
Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer’s disease. PLoS One. 2009;4:e6294.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS amyloid-β in Alzheimer’s disease. Science. 2010;330:1774.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013;74:826–36.
Article
PubMed
PubMed Central
CAS
Google Scholar
Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.
Article
PubMed
Google Scholar
Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission computed tomography core. Alzheimers Dement. 2010;6:221–9.
Article
PubMed
PubMed Central
Google Scholar
Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050–68.
Article
PubMed
Google Scholar
Klein G, Sampat M, Staewen D, Scott D, Suhy J. Effect size and spatial smoothing of ADNI florbetapir and FDG PET. Washington, DC, USA: Poster presented at the Alzheimer’s Association International Conference (AAIC); 2015.
Google Scholar